Member Health Of Niti Aayog
- All
- News
- Videos
-
Decision On Zydus Cadila's Vaccine Prices Soon, Says NITI Aayog
The discussion on the pricing of Zydus Cadila's COVID-19 vaccine ZyCoV-D is underway, said Dr VK Paul, Member (Health) NITI Aayog on Tuesday.
-
Masks Will Stay Through 2022, Need Drug Against Covid: NITI Aayog Member
Dr VK Paul, the NITI Aayog Member for Health, said battling Covid will require a combination of vaccines, effective drugs, and disciplined social behaviour. He did not ruling out a third wave and cautioned against the risky festival lying ahead.
-
Looking Very Deeply Into Issue Of Vaccine Booster Dose: NITI Aayog Member
The national expert committee on COVID-19 vaccination has discussed the issue of giving booster vaccine dose and it is being looked into very deeply, NITI Aayog Member (Health) Dr VK Paul said on Tuesday.
-
India On Track To Achieve Doctor-Population Ratio: NITI Aayog Member
India is well on the path to achieving the World Health Organisation-recommended ratio of one doctor per thousand population by 2024 and is increasing the number of hospital beds from 11 lakh to 22 lakh, NITI Aayog member Vinod Paul said on Monday.
-
Serosurvey Does Not Cover Granularity At State Level: NITI Aayog Member
Serosurveys cannot be extrapolated to estimate mortality rates of COVID-19 or undercounting of the number of coronavirus infections as they are not meant to cover granularity at the level of the state, NITI Aayog member (health) Dr VK Paul has said.
-
India Has Been Offered 7.5 Million Doses Of Moderna COVID-19 Vaccine Through COVAX: WHO
The Government of India is holding discussions with COVID-19 manufacturers Moderna and Pfizer over several issues including indemnity waiver, Dr VK Paul, Member (Health), NITI Aayog said on Friday.
-
Manufacturers To Decide Price Of Covid Vaccines To Private Sectors: Niti Aayog
The price of COVID-19 vaccines to private sectors (hospitals) will be decided by vaccine manufacturers, informed Member (health) NITI Aayog Dr VK Paul on Tuesday.
-
India Overtakes US, Has More Number Of People With 1st Dose Of Vaccine
Member Health NITI Aayog Dr VK Paul on Friday said India has overtaken the United States in terms of the number of people who have received the first dose of COVID-19 vaccine.
-
Pfizer's Indemnity Request Being Examined, Supply Likely In July: Centre
The government is examining Pfizer's request for indemnity and will take a decision in the larger interest of people and on merit, NITI Aayog Member (Health) VK Paul said today.
-
Vaccination Of Frontline Workers In Delhi Below National Average: Centre
The inoculation of frontline and healthcare workers against coronavirus in Delhi is less than the national average, Member (Health) of the Niti Aayog VK Paul said on Saturday.
-
No Significant Shift In Age Distribution Of Covid Cases: NITI Ayog Member
There is no significant shift in the age distribution of COVID-19 cases in the second wave as compared to the first one, said Dr VK Paul, Member (Health) of the NITI Aayog, on Monday.
-
"No Signal Of Concern" Over AstraZeneca Covid Vaccine Shots: NITI Aayog
There is no signal of concern regarding the use of Oxford-AstraZeneca COVID-19 vaccine in the country, said Member (Health) of the Niti Aayog Dr VK Paul, amid speculations and subsequent review of possible side-effects of the vaccine in different countries.
-
No Case Of South African Covid Variant Found In India: Centre
No case of South African variant of COVID-19 virus has been found in the country so far, said NITI Aayog member (health) Dr VK Paul on Tuesday.
-
Panel May Recommend Using Corporate Social Fund For Vaccination: NITI Aayog Official
A high-level committee on COVID-19 is likely to recommend allowing corporates to use CSR (corporate social responsibility) funds for vaccinating employees and local communities to control COVID-19, Niti Aayog Member (Health) VK Paul said on Monday.
-
Covishield, Covaxin Safe, Side-Effects Negligible: NITI Aayog Member
Covishield and Covaxin, the two COVID-19 vaccines which have received Emergency Use Authorisation have been tested on thousands of people and side-effects are negligible, Dr VK Paul, Member (Health), NITI Aayog, said on Tuesday and noted that the two "are safest of the vaccines".
-
Decision On Zydus Cadila's Vaccine Prices Soon, Says NITI Aayog
The discussion on the pricing of Zydus Cadila's COVID-19 vaccine ZyCoV-D is underway, said Dr VK Paul, Member (Health) NITI Aayog on Tuesday.
-
Masks Will Stay Through 2022, Need Drug Against Covid: NITI Aayog Member
Dr VK Paul, the NITI Aayog Member for Health, said battling Covid will require a combination of vaccines, effective drugs, and disciplined social behaviour. He did not ruling out a third wave and cautioned against the risky festival lying ahead.
-
Looking Very Deeply Into Issue Of Vaccine Booster Dose: NITI Aayog Member
The national expert committee on COVID-19 vaccination has discussed the issue of giving booster vaccine dose and it is being looked into very deeply, NITI Aayog Member (Health) Dr VK Paul said on Tuesday.
-
India On Track To Achieve Doctor-Population Ratio: NITI Aayog Member
India is well on the path to achieving the World Health Organisation-recommended ratio of one doctor per thousand population by 2024 and is increasing the number of hospital beds from 11 lakh to 22 lakh, NITI Aayog member Vinod Paul said on Monday.
-
Serosurvey Does Not Cover Granularity At State Level: NITI Aayog Member
Serosurveys cannot be extrapolated to estimate mortality rates of COVID-19 or undercounting of the number of coronavirus infections as they are not meant to cover granularity at the level of the state, NITI Aayog member (health) Dr VK Paul has said.
-
India Has Been Offered 7.5 Million Doses Of Moderna COVID-19 Vaccine Through COVAX: WHO
The Government of India is holding discussions with COVID-19 manufacturers Moderna and Pfizer over several issues including indemnity waiver, Dr VK Paul, Member (Health), NITI Aayog said on Friday.
-
Manufacturers To Decide Price Of Covid Vaccines To Private Sectors: Niti Aayog
The price of COVID-19 vaccines to private sectors (hospitals) will be decided by vaccine manufacturers, informed Member (health) NITI Aayog Dr VK Paul on Tuesday.
-
India Overtakes US, Has More Number Of People With 1st Dose Of Vaccine
Member Health NITI Aayog Dr VK Paul on Friday said India has overtaken the United States in terms of the number of people who have received the first dose of COVID-19 vaccine.
-
Pfizer's Indemnity Request Being Examined, Supply Likely In July: Centre
The government is examining Pfizer's request for indemnity and will take a decision in the larger interest of people and on merit, NITI Aayog Member (Health) VK Paul said today.
-
Vaccination Of Frontline Workers In Delhi Below National Average: Centre
The inoculation of frontline and healthcare workers against coronavirus in Delhi is less than the national average, Member (Health) of the Niti Aayog VK Paul said on Saturday.
-
No Significant Shift In Age Distribution Of Covid Cases: NITI Ayog Member
There is no significant shift in the age distribution of COVID-19 cases in the second wave as compared to the first one, said Dr VK Paul, Member (Health) of the NITI Aayog, on Monday.
-
"No Signal Of Concern" Over AstraZeneca Covid Vaccine Shots: NITI Aayog
There is no signal of concern regarding the use of Oxford-AstraZeneca COVID-19 vaccine in the country, said Member (Health) of the Niti Aayog Dr VK Paul, amid speculations and subsequent review of possible side-effects of the vaccine in different countries.
-
No Case Of South African Covid Variant Found In India: Centre
No case of South African variant of COVID-19 virus has been found in the country so far, said NITI Aayog member (health) Dr VK Paul on Tuesday.
-
Panel May Recommend Using Corporate Social Fund For Vaccination: NITI Aayog Official
A high-level committee on COVID-19 is likely to recommend allowing corporates to use CSR (corporate social responsibility) funds for vaccinating employees and local communities to control COVID-19, Niti Aayog Member (Health) VK Paul said on Monday.
-
Covishield, Covaxin Safe, Side-Effects Negligible: NITI Aayog Member
Covishield and Covaxin, the two COVID-19 vaccines which have received Emergency Use Authorisation have been tested on thousands of people and side-effects are negligible, Dr VK Paul, Member (Health), NITI Aayog, said on Tuesday and noted that the two "are safest of the vaccines".
